CHARM study gives heart failure hope
Major new research has backed the use of angiotensin-2-receptor antagonists (A2As) for patients with chronic heart failure.
The drug improved quality of life in more than a third of patients, according to results from the CHARM study.
The research, involving 7,600 patients, showed candesartan, an angiotensin-2-receptor blocker, improved New York Heart Association class in 35.4 per cent of patients with heart failure.
Professor John McMurray, professor of medical cardiology at the University of Glasgow, presented the findings earlier this month at the American College of Cardiology conference in New Orleans. He told Pulse the results had 'significant implications' for clinical practice.
NICE sparked controversy for failing to take account of emerging evidence on the use of A2As in heart failure when it issued guidelines last July.
It recommended GPs considered the drugs for patients who were intolerant of ACE inhibitors, which occurs in about 15 per cent of patients.